Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination

Appendix

Appendix Figure. Results of 90% plaque reduction neutralization tests (PRNT$_{90}$) against 3 SARS-CoV-2 strains in relation to binding antibody unit per mL (BAU/mL). Serum samples were collected from 20 SARS-CoV-2–naive participants who received 2 BNT162b2 (Pfizer-BionTech; Pfizer,
https://www.pfizer.com) doses and a booster BNT162b2 dose. Titers were measured by using Liaison TrimericS IgG Quantitative immunoassay (DiaSorin, https://www.diasorin.com). A) PRNT\textsubscript{90} titers of the ancestral SARS-CoV-2 strain (GenBank [https://www.ncbi.nlm.nih.gov/genbank] accession no. ON055855). B) PRNT\textsubscript{90} titers of the BA.1 SARS-CoV-2 strain (GenBank accession no. ON055874). C) PRNT\textsubscript{90} titers of the BA.2 SARS-CoV-2 strain (GenBank accession no. ON055857).